Press Releases 2010
BIOCRATES expands management board
New Chief Technology Officer (CTO) Dr. Ralph Zahn
07.12.2010 – The Austrian BIOCRATES Life Sciences AG, pioneer in the development of metabolic Biomarkers, has employed Dr. Ralph Zahn as new CTO (Chief Technology Officer), since October 2010. „The constant development of our products and the affiliated technical and scientific assignments made a CTO necessary. Dr. Zahn and his expertise are a valuable enrichment to our organisation“, says Elgar Schnegg, MBA, CEO of BIOCRATES.
Press Release in English
Press Release in German
Austrian BIOCRATES Life Sciences AG announces launch of its first metabolomics-based clinical research kit—MetaDisIDQ Kit
15.11.2010 - Austrian BIOCRATES Life Sciences AG, a pioneer in the development of metabolic biomarker panels, announces the launch of its first clinical research kit product, the MetaDisIDQ Kit. With this latest addition to its product and services portfolio, the maker of the world’s first mass-spectrometry–based metabolomics kits now provides additional derived parameters (sums and ratios) within the software for clinical research projects. Quantifying 181 metabolites from 5 compound classes, the MetaDisIDQ Kit is an excellent choice for clinical researchers in the area of diabetology and/or nutritional science looking for a cost-effective solution to quantify metabolites under quality-controlled conditions in their own laboratory.Press Release in English
Austrian BIOCRATES Life Sciences AG announces launch of its second mass- spectrometry-based metabolomics research kit—AbsoluteIDQ p180 Kit
06.09.10 - Austrian BIOCRATES Life Sciences AG, a pioneer in the development of metabolite biomarker panels, announces the launch of its second kit product, the AbsoluteIDQ p180 Kit. With this latest addition to its product and services portfolio, the maker of the world’s first mass-spectrometry–based metabolomics kit, the AbsoluteIDQ p150 Kit, now provides an even broader scope of capabilities in determining metabolic changes in cell culture, preclinical, and clinical research projects. Quantifying 186 metabolites from 5 compound classes, the AbsoluteIDQ p180 Kit is an excellent choice for researchers looking for a cost-effective solution to measure metabolites under quality-controlled conditions in their own laboratory.
Press Release in English
Press Release in German
Austrian BIOCRATES Life Sciences AG and Swiss Selexis SA join forces to further optimize high-yield mammalian cell cultures for the production of protein pharmaceuticals
30.08.2010 - Austrian BIOCRATES Life Sciences AG, a prime developer of metabolite biomarkers, and Swiss Selexis SA, a leading biotech company designing high-performance and stable mammalian cell lines for the production of protein drugs, have entered into a co-development agreement with a view to further increasing the drug substance yields from mammalian cell cultures for the pharmaceutical industry. Under the agreement, both parties will combine their knowledge to help lower overall manufacturing costs for pharmacologically active proteins.
Press Release in English
Press Release in German
BIOCRATES erhält erp-Technologiekredit
26.08.2010 - Die BIOCRATES Life Sciences AG, ein in Österreich ansässiges Biotechnologieunternehmen mit Spezialisierung auf diagnostische Biomarker, hat von der Austria Wirtschaftsservice – aws – einen erp-Kredit1 mit einem Gesamtrahmen von 3 Millionen Euro erhalten.
Press Release in German
BIOCRATES Life Sciences AG nominiert für den Industriepreis 2010
22.04.2010 - Die österreichische BIOCRATES Life Sciences AG, ein führender Entwickler von Metabolischen Biomarkern, hat beim deutschen Industriepreis 2010 eine von drei heiß begehrten Nominierungen in der Kategorie Biotechnologie erhalten.
Press Release in German
BIOCRATES Life Sciences AG joins SysKid, a European research consortium refining the diagnosis and treatment of chronic kidney disease
31.03.2010 - Austrian BIOCRATES Life Sciences AG, a prime developer of metabolite biomarkers with an impressive track record in kidney disease research, has joined a multi-partner European research program dedicated to improving the diagnosis and treatment of chronic kidney disease (CKD), i.e., the ‘Systems Biology towards Novel Chronic Kidney Disease Diagnosis and Treatment’ project — or SysKid.
Press Release in English
Press Release in German
Neue Finanzierungsrunde der BIOCRATES Life Sciences AG erfolgreich gestartet
25.03.2010 - Die österreichische BIOCRATES Life Sciences AG, ein führender Entwickler von Metabolischen Biomarkern, hat neues Kapital in Höhe von 1,2 Millionen Euro erhalten. Eine weitere Tranche in der selben Höhe im heurigen Jahr ist wahrscheinlich. Wie das Unternehmen mitteilte, wird es diese Mittel einsetzen, um in seine Biomarkerforschung zu investieren, da dieser Geschäftszweig das größte Wachstumspotential hat.
Press Release in German
Austrian biomarker expert BIOCRATES Life Sciences AG and Canadian CHENOMX Inc sign co-marketing agreement
10.03.2010 - The agreement entered between Austrian BIOCRATES Life Sciences AG and the Canadian company CHENOMX Inc is a significant step towards realizing the goal of further personalizing both drug development and medical practice. Under the agreement, both companies will be able to offer complementary metabolomic analyses, service a joint customer base, and collaborate in promoting each other’s services.
Press Release in English
Press Release in German
German Research Team Elucidates Genetic Variations in Human Metabolism
18.02.2010 - Recent advances in biochemistry have made it possible to take a fingerprint of an individual’s metabolism. A group of German scientists have developed a strategy to assess the genetic basis of variations in human metabolism by coupling genetic and metabolic profiling. Responsibility for the metabolite part of the profiling exercise lay with the Austrian company BIOCRATES Life Sciences AG, a cutting-edge developer of novel metabolite biomarkers. The findings presented mark an additional step towards the development of novel biomarkers of unprecedented specificity and sensitivity, paving the way for the design of personalized medicines.
Press Release in English
Press Release in German
Improving children’s health through state-of-the-science biomarkers
10.02.2010 - First International Pediatric Biomarker Symposium, co-organized by Austrian biomarker company BIOCRATES Life Sciences AG, convened in Innsbruck, Austria, from 4–6 February 2010.
Recent technological advances have been providing unprecedented insights into the genetic, protein, and metabolite setup of the human organism. These developments in the area of personalized medicine have also been harnessed to the benefit of the youngest members of our society—newborns, infants, and children. One of the co-organizers of the symposium was the Austrian company BIOCRATES Life Sciences AG, a cutting-edge developer of novel metabolite biomarkers, which are effectively being used to improve the health of children. Yet, the untapped potential of biomarkers is huge, as reconfirmed in numerous conference presentations from experts around the world.
Press Release in English
Press Release in German
